Signals BioDesign™
Revvity Signals BioDesign is a streamlined, enterprise-ready SaaS molecular biology product that improves large molecule design. Focusing on core cloning features, it avoids unnecessary complexity while supporting high-throughput workflows capable of modelling thousands of plasmids. Designed for any organization - from small and medium biotech to global pharma - Signals BioDesign integrates with other Revvity Signals solutions…
Receive your quote directly from the manufacturer.
Molecular biologists face challenges that extend beyond the limitations of individual tools that support isolated tasks rather than integrated workflows. Scientists need to know why certain cloning strategies work, how to optimize primer design based on historical success rates, and how to improve constructs over time. Yet knowledge remains trapped with individuals rather than becoming organizational expertise. The industry lacks products that can recommend optimal cloning approaches based on target sequences, predict potential issues before bench work begins, or automatically suggest improvements based on similar successful projects.
Signals BioDesign provides:
• Simple, effective molecular biology tools built for scale
• Connectivity to other Revvity Signals solutions
• The ability to unlock molecular biology insights and organizational knowledge
Mastering multimodal drug discovery
Modern drug discovery is becoming increasingly multimodal. Alongside traditional small molecules, researchers are advancing protein degraders, antibody-drug conjugates, RNA therapeutics, and cell and gene therapies, each generating unique datasets across chemistry, biology, and translational research. While these modalities offer exciting therapeutic opportunities, they also create new challenges around data management, collaboration, and decision-making.
Many organizations continue to rely on disconnected informatics systems that were built to support individual workflows rather than integrated discovery. As data becomes increasingly fragmented across teams and technologies, it can be difficult to connect insights, revisit historical results, and fully leverage emerging AI and machine learning approaches. Building unified, AI-ready research environments is becoming critical for accelerating discovery while maintaining scientific rigor.
This SelectScience guide, developed in partnership with Revvity Signals, explores how connected informatics ecosystems can help streamline multimodal drug discovery workflows. Through expert perspectives, real-world examples, and practical insights, discover how organizations are breaking down data silos, supporting collaboration across disciplines, and enabling more efficient progression through the design-make-test-decide (DMTA) cycle.
Download this SelectScience guide to explore:
- The operational challenges facing modern multimodal drug discovery
- Why emerging therapeutic modalities demand integrated informatics strategies
- How workflow fragmentation slows research and decision-making
- Approaches for standardizing discovery with unified digital ecosystems
- Strategies for connecting molecular biology and therapeutic design workflows
- Supporting protein degraders, antibodies, RNA therapeutics, and other emerging modalities
- How structured, AI-ready data can help accelerate discovery programs
Resource details:
- Document type: SelectScience guide
- Page count: 50
- Read time: 90 mins
- Edition: 1st
Signals Synergy breaks down sponsor-CRO data silos
As sponsor–CRO collaborations become even more central to drug discovery, fragmented data and manual processes continue to slow progress – but more structured, connected workflows are beginning to reshape how teams share and act on information
